​

Foghorn Therapeutics (FHTX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

FHTX Stock Forecast

Foghorn Therapeutics (FHTX) stock forecast, based on 7 Wall Street analysts, predicts a 12-month average price target of $13.00, with a high of $13.00 and a low of $13.00. This represents a 242.11% increase from the last price of $3.80.

$3 $5 $7 $9 $11 $13 High: $13 Avg: $13 Low: $13 Last Closed Price: $3.8

FHTX Stock Rating

Foghorn Therapeutics stock's rating consensus is Buy, based on 7 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 7 0 7 Strong Sell Sell Hold Buy Strong Buy

FHTX Price Target Upside V Benchmarks

TypeNameUpside
StockFoghorn Therapeutics242.11%
SectorHealthcare Stocks 35.94%
IndustryBiotech Stocks 83.61%

Price Target Trends

1M3M12M
# Anlaysts--3
Avg Price Target--$14.00
Last Closing Price$3.80$3.80$3.80
Upside/Downside--268.42%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25151--7
Mar, 25251--8
Feb, 25241--7
Jan, 25241--7
Dec, 24241--7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 17, 2024Foghorn Therapeutics to $H.C. Wainwright$13.00$6.26107.67%242.11%
Sep 24, 2024Vikram PurohitMorgan Stanley$9.00$9.32-3.43%136.84%
Aug 19, 2024Gavin Clark-GartnerEvercore ISI$20.00$6.26219.49%426.32%
Jan 05, 2023BMO Capital$20.00$6.53206.28%426.32%
Nov 21, 2022Morgan Stanley$14.00$7.8777.89%268.42%
Aug 23, 2022Vikram PurohitMorgan Stanley$15.00$10.8937.74%294.74%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 30, 2025B. RileyBuyinitialise
Sep 24, 2024Morgan StanleyEqual-WeightEqual-Weighthold
Sep 03, 2024JefferiesBuyinitialise
Aug 19, 2024Evercore ISIOutperforminitialise
Jun 29, 2023Goldman SachsBuyBuyhold
Jan 05, 2023BMO CapitalOutperforminitialise
Nov 21, 2022Morgan StanleyEqual-WeightEqual-Weighthold
Aug 23, 2022Morgan StanleyOverweightHolddowngrade
May 23, 2022Morgan StanleyOverweightOverweighthold

Financial Forecast

EPS Forecast

$-7 $-6 $-5 $-4 $-3 $-2 $-1 $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.90$-2.78$-2.62$-2.34$-1.58----
Avg Forecast$-4.20$-2.60$-2.39$-2.41$-1.60$-1.20$-1.01$-1.20$-0.65
High Forecast$-2.85$-1.77$-1.45$-2.39$-1.49$-0.74$-0.38$-0.44$-0.41
Low Forecast$-6.22$-3.86$-3.59$-2.46$-1.74$-1.58$-1.53$-2.60$-0.89
Surprise %-54.76%6.92%9.62%-2.90%-1.25%----

Revenue Forecast

$0 $19M $38M $57M $76M $95M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$430.00K$1.32M$19.23M$34.16M$22.60M----
Avg Forecast$686.00K$1.32M$22.92M$32.43M$29.46M$33.36M$38.50M$39.63M$70.81M
High Forecast$940.89K$1.80M$31.77M$34.96M$41.19M$42.89M$39.29M$41.18M$91.03M
Low Forecast$516.84K$990.88K$15.97M$29.23M$25.35M$24.03M$37.71M$38.09M$51.01M
Surprise %-37.32%0.29%-16.11%5.32%-23.27%----

Net Income Forecast

$-300M $-240M $-180M $-120M $-60M $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-69.78M$-103.23M$-108.87M$-98.43M$-86.62M----
Avg Forecast$-176.08M$-109.30M$-100.21M$-101.78M$-67.92M$-48.58M$-40.21M$-95.00M$-27.13M
High Forecast$-119.64M$-74.26M$-60.73M$-100.11M$-62.66M$-30.89M$-16.09M$-18.66M$-17.27M
Low Forecast$-261.14M$-162.10M$-150.50M$-103.45M$-73.17M$-66.28M$-64.34M$-108.95M$-37.20M
Surprise %-60.37%-5.56%8.65%-3.30%27.54%----

FHTX Forecast FAQ

Is Foghorn Therapeutics stock a buy?

Foghorn Therapeutics stock has a consensus rating of Buy, based on 7 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Foghorn Therapeutics is a favorable investment for most analysts.

What is Foghorn Therapeutics's price target?

Foghorn Therapeutics's price target, set by 7 Wall Street analysts, averages $13 over the next 12 months. The price target range spans from $13 at the low end to $13 at the high end, suggesting a potential 242.11% change from the previous closing price of $3.8.

How does Foghorn Therapeutics stock forecast compare to its benchmarks?

Foghorn Therapeutics's stock forecast shows a 242.11% upside, outperforming the average forecast for the healthcare stocks sector (35.94%) and outperforming the biotech stocks industry (83.61%).

What is the breakdown of analyst ratings for Foghorn Therapeutics over the past three months?

  • April 2025: 14.29% Strong Buy, 71.43% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 25.00% Strong Buy, 62.50% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 28.57% Strong Buy, 57.14% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.

What is Foghorn Therapeutics’s EPS forecast?

Foghorn Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.2, marking a -24.05% decrease from the reported $-1.58 in 2024. Estimates for the following years are $-1.01 in 2026, $-1.2 in 2027, and $-0.65 in 2028.

What is Foghorn Therapeutics’s revenue forecast?

Foghorn Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $33.36M, reflecting a 47.58% increase from the reported $22.6M in 2024. The forecast for 2026 is $38.5M, followed by $39.63M for 2027, and $70.8M for 2028.

What is Foghorn Therapeutics’s net income forecast?

Foghorn Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-48.584M, representing a -43.91% decrease from the reported $-86.62M in 2024. Projections indicate $-40.214M in 2026, $-94.999M in 2027, and $-27.125M in 2028.